Abstract 1195P
Background
Li-Fraumeni syndrome (LFS) is a rare autosomal dominant condition, caused by an alteration in the TP53 gene. Individuals with LFS are susceptible to developing a wide range of malignancies. National and international guidelines recommend annual WB-MRI scan for screening for cancer; however, WB-MRI is not yet implemented in this setting worldwide or in the UK. SIGNIFIED is a cost-effectiveness and implementation project that will assess the value of screening WB-MRI in LFS.
Methods
Individuals with LFS, with no cancer diagnosis in the past 5 years, were scanned using two WB-MRI, 12 months apart. Diffusion-weighted MRI images were acquired from vertex to feet. Incidental findings were further investigated and discussed in a specialist MDT meeting.
Results
Fifty-four asymptomatic individuals with LFS were recruited between May 2022 and July 2023 from Cancer Genetic Units across the United Kingdom. 40 females (74%) and 14 males (26%) were enrolled. The median age at recruitment was 42 years (range 18-70). Following 1st scan performed in 54 individuals, 16.6% of patients had a suspicious lesion that was biopsied/excised (N=9), and less than half (44%, N=4) had a confirmed cancer. Following 2nd scan performed in 44 individuals, 13.6% of patients had a suspicious lesion that was biopsied/excised (N=6) and in 83% of cases (N=5), a cancer diagnosis was confirmed. There was increased confidence in benignity when a comparator scan was available. In total, 9 cancers were detected and 66% (N=6) were diagnosed at stages 0-2 and underwent curative treatment. A further stage 3 pancreatic cancer (T4N0M0) was diagnosed and the patient received peri-operative chemotherapy and surgery with curative intent.
Conclusions
Overall, 9 cancers in 54 individuals were diagnosed with the help of WB-MRI. The rate of cancers detected in this cohort was higher than expected in a general population, consistent with the known risk of cancers in the LFS population. WB-MRI is a valuable and useful radiological tool for the detection of early cancers in LFS and our data support guidelines that it should be implemented as a regular screening test for this population. A health economics analysis is currently ongoing.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Small Business Research Initiative (SBRI) Healthcare.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
835P - Genetic, epigenetic, and clinical significance of Wilms’ tumor 1 (WT1) gene in acute myeloid leukemia
Presenter: Harsh Goel
Session: Poster session 09
Resources:
Abstract
836P - A prospective study to evaluate the prognostic implications and molecular mechanism of SLC40A1 gene in primary acute myeloid leukemia
Presenter: Harsh Goel
Session: Poster session 09
Resources:
Abstract
837P - Expression analysis, clinical significance and potential function of ALOX5AP in acute myeloid leukemia
Presenter: Harsh Goel
Session: Poster session 09
Resources:
Abstract
838P - Bayesian modeling in the survival analysis of patients with multiple myeloma with emphasis on missing data analysis
Presenter: Nelson Cruz Gutierrez
Session: Poster session 09
839P - Preliminary results from a phase II study of amulirafusp alfa (IMM0306) in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma
Presenter: jianliang yang
Session: Poster session 09
840P - Orelabrutinib-based regimens in chronic lymphocytic leukemia with comorbidities: A real-world study
Presenter: Xun Lai
Session: Poster session 09
841P - Transforming the landscape of pediatric AML treatment: A cutting-edge SCT prognostic model
Presenter: Hua Yang
Session: Poster session 09
Resources:
Abstract
842P - Exploring the association of side-effects with depression in patients with chronic lymphocytic leukemia who have received treatment: An analysis of the lymphoma coalition’s 2022 global patient survey
Presenter: Natacha Bolanos Fernandez
Session: Poster session 09
843P - Challenges and insights in treating Langerhans cell histiocytosis: Persistent mutations and novel therapeutic approaches
Presenter: Marzieh NASHVI
Session: Poster session 09
844TiP - Orelabrutinib combined with rituximab for the treatment of elderly patients with newly diagnosed non-GCB diffuse large B-cell lymphoma (DLBCL) under the guidance of genetic subtype: A prospective, multicenter, single-arm, response-adaptive clinical study (Origin)
Presenter: Wanzhuo Xie
Session: Poster session 09